SSGI (OTCMKTS:VICP – Get Free Report) and NVR (NYSE:NVR – Get Free Report) are both construction companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.
Earnings & Valuation
This table compares SSGI and NVR”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SSGI | N/A | N/A | -$690,000.00 | ($0.04) | -36.50 |
| NVR | $10.09 billion | 1.70 | $1.34 billion | $410.17 | 15.51 |
Volatility and Risk
SSGI has a beta of 4.45, suggesting that its share price is 345% more volatile than the S&P 500. Comparatively, NVR has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for SSGI and NVR, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SSGI | 0 | 0 | 0 | 0 | 0.00 |
| NVR | 1 | 3 | 3 | 0 | 2.29 |
NVR has a consensus price target of $7,478.50, suggesting a potential upside of 17.52%. Given NVR’s stronger consensus rating and higher probable upside, analysts plainly believe NVR is more favorable than SSGI.
Institutional and Insider Ownership
83.7% of NVR shares are owned by institutional investors. 6.0% of SSGI shares are owned by company insiders. Comparatively, 8.6% of NVR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares SSGI and NVR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SSGI | N/A | N/A | N/A |
| NVR | 12.93% | 32.66% | 21.16% |
Summary
NVR beats SSGI on 12 of the 13 factors compared between the two stocks.
About SSGI
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
About NVR
NVR, Inc. operates as a homebuilder in the United States. The company operates through, Homebuilding and Mortgage Banking segments. It engages in the construction and sale of single-family detached homes, townhomes, and condominium buildings under the Ryan Homes, NVHomes, and Heartland Homes names. The company markets its Ryan Homes products to first-time and first-time move-up buyers; and NVHomes and Heartland Homes products to move-up and luxury buyers. It also provides various mortgage related services to its homebuilding customers, as well as brokers title insurance; performs title searches in connection with mortgage loan closings; and sells mortgage loans to investors in the secondary markets on a servicing released basis. The company primarily serves in Maryland, Virginia, West Virginia, Delaware, New Jersey, Eastern Pennsylvania, New York, Ohio, Western Pennsylvania, Indiana, Illinois, North Carolina, Georgia, South Carolina, Florida, Tennessee, and Washington, D.C. NVR, Inc. was founded in 1980 and is headquartered in Reston, Virginia.
Receive News & Ratings for SSGI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SSGI and related companies with MarketBeat.com's FREE daily email newsletter.
